Short at­tack­er Sahm Ad­ran­gi draws crosshairs over a fa­vorite of Sanofi’s new CEO — with PhII da­ta loom­ing

Sahm Ad­rang Ker­ris­dale

Ker­ris­dale chief Sahm Ad­ran­gi took a lengthy break from his se­ries of biotech short at­tacks af­ter his chief an­a­lyst in the field pulled up stakes and went so­lo. But he’s mak­ing a re­turn to drug de­vel­op­ment this morn­ing, draw­ing crosshairs over a com­pa­ny that’s one of new Sanofi CEO Paul Hud­son’s fa­vorite col­lab­o­ra­tors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER